Roy Fleischmann, MD

Roy Fleischmann, MD

Clinical Professor of Medicine 
University of Texas Southwestern Medical Center at Dallas 
Co-Director, Division of Rheumatology 
Texas Health Presbyterian Medical Center and Co-Medical Director 
Metroplex Clinical Research Center 

Related Videos

Can you review the mechanism of action of IL-6 inhibitors in RA, and what we have learned from trials evaluating the safety and efficacy of sarilumab, tocilizumab, and other drugs in this class? Video

Can you review the mechanism of action of IL-6 inhibitors in RA, and what we have learned from trials evaluating the safety and efficacy of sarilumab, tocilizumab, and other drugs in this class?

Can you provide an overview of the mechanism of action of IL-6 inhibitors in RA, rationale for their use, and what we have learned from landmark trials evaluating the safety and efficacy of sarilumab, tocilizumab, and other drugs in this class?

How do you differentiate among the available biologics with respect to their propensity to produce side effects or other treatment complications? Video

How do you differentiate among the available biologics with respect to their propensity to produce side effects or other treatment complications?

How do you differentiate among the available biologics with respect to their propensity to produce side effects or other treatment complications?

Are there any specific patient profiles in RA or biomarker signatures that would suggest that a patient might respond better to one biologic DMARD and MOA -- including IL-6 inhibition -- versus another? Video

Are there any specific patient profiles in RA or biomarker signatures that would suggest that a patient might respond better to one biologic DMARD and MOA -- including IL-6 inhibition -- versus another?

Are there any specific patient profiles in RA or biomarker signatures that would suggest that an individual patient might respond better to one biologic DMARD and MOA — including IL-6 inhibition — versus another?

Can you discuss the recommendations for biologic therapy in RA issued by the ACR guidelines and compare these to the EULAR guidelines for RA? Where do IL-6 inhibitors fall into the treatment pathways? Video

Can you discuss the recommendations for biologic therapy in RA issued by the ACR guidelines and compare these to the EULAR guidelines for RA? Where do IL-6 inhibitors fall into the treatment pathways?

Can you discuss the critical recommendations for biologic therapy in RA issued by the ACR guidelines and compare these to the recently reported EULAR guidelines for RA? How are they similar? How are they different? Where do IL-6 inhibitors ...

EULAR guidelines--as well as ACR recommendations for RA management--are relatively agnostic as far as which biologic DMARD should be used to intensify RA therapy after a methotrexate or other synthetic DMARD failure. What factors do you consider when deciding whether an IL-6 inhibitor is the best option? Video

EULAR guidelines--as well as ACR recommendations for RA management--are relatively agnostic as far as which biologic DMARD should be used to intensify RA therapy after a methotrexate or other synthetic DMARD failure. What factors do you consider when deciding whether an IL-6 inhibitor is the best option?

The new EULAR guidelines—as well as ACR recommendations for RA management—are relatively agnostic as far as which biologic DMARD should be used to intensify RA therapy after a methotrexate or other synthetic DMARD failure. What factors ...

Considering results from SARIL-RA-TARGET, SARIL-RA-MOBILITY, EXTEND, and MONARCH, how do you differentiate among agents and patients to identify ideal candidates for this IL-6 inhibitor vs. others? Video

Considering results from SARIL-RA-TARGET, SARIL-RA-MOBILITY, EXTEND, and MONARCH, how do you differentiate among agents and patients to identify ideal candidates for this IL-6 inhibitor vs. others?

Considering the positive results from the SARIL-RA-TARGET, SARIL-RA-MOBILITY and EXTEND studies, as well as the recently reported MONARCH study, how do you differentiate among the agents and RA patients to identify ideal candidates for ...

What key clinical parameters, biomarkers, symptoms, and patient-reported outcomes do you prioritize when determining the need for escalating therapy in RA? Video

What key clinical parameters, biomarkers, symptoms, and patient-reported outcomes do you prioritize when determining the need for escalating therapy in RA?

What key clinical parameters, biomarkers, symptoms, and patient-reported outcomes do you prioritize when determining the need for escalating therapy in RA?

What clinical trials have been conducted or are in progress evaluating IL-6 inhibitors for the management of RA? Can you discuss tocilizumab and sarilumab and the specific trial designs? Video

What clinical trials have been conducted or are in progress evaluating IL-6 inhibitors for the management of RA? Can you discuss tocilizumab and sarilumab and the specific trial designs?

What clinical trials have been conducted and/or are currently in progress evaluating IL-6 inhibitors for the management of RA? Can you discuss both tocilizumab and sarilumab and the specific trial designs?

What are the side effects of TNF inhibitors and how do you manage risk for infection? And how does this side effect profile compare to that of IL-6 inhibitors? Video

What are the side effects of TNF inhibitors and how do you manage risk for infection? And how does this side effect profile compare to that of IL-6 inhibitors?

What are the side effects of TNF inhibitors and how do you manage risk for infection? And how does this side effect profile compare to that of IL-6 inhibitors?